2023
Beyond Survival: Adverse Events and Care Delivery Outcomes after Early Liver Cancer Treatment in a Nationally Representative Cohort
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown R, Fortune B, Talenfeld A, Madoff D, Ibrahim S, Johnson M, Sedrakyan A. Beyond Survival: Adverse Events and Care Delivery Outcomes after Early Liver Cancer Treatment in a Nationally Representative Cohort. Journal Of Vascular And Interventional Radiology 2023, 34: 1997-2005.e3. PMID: 37468093, DOI: 10.1016/j.jvir.2023.07.010.Peer-Reviewed Original ResearchConceptsLiver transplantSurgical resectionHepatocellular carcinomaLT cohortBiliary injuryReadmission ratesAbscess formationIntensive care unit-level careLess healthcare utilizationNationally Representative CohortInitial hospital stayICU-level careAdverse event ratesEnd Results ProgramSmall hepatocellular carcinomaCare delivery outcomesFisher's exact testHealthcare Common Procedure Coding SystemChi-square testLow-intensity careLiver cancer treatmentPostprocedural hemorrhageHospital stayAdverse eventsSecondary outcomesBowel Injury during Percutaneous Radiologic Gastrostomy Tube Placement: A Case Series
Deshmukh A, Ali R, Madoff D, Silin D, Zuckerman D, Cornman-Homonoff J. Bowel Injury during Percutaneous Radiologic Gastrostomy Tube Placement: A Case Series. Journal Of Vascular And Interventional Radiology 2023, 34: 1462-1465. PMID: 37164038, DOI: 10.1016/j.jvir.2023.04.024.Peer-Reviewed Original Research
2022
Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study
Gregory J, Tselikas L, Allimant C, de Baere T, Bargellini I, Bell J, Bilbao JI, Bouvier A, Chapiro J, Chiesa C, Decaens T, Denys A, Duran R, Edeline J, Garin E, Ghelfi J, Helmberger T, Irani F, Lam M, Lewandowski R, Liu D, Loffroy R, Madoff DC, Mastier C, Salem R, Sangro B, Sze D, Vilgrain V, Vouche M, Guiu B, Ronot M. Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study. European Journal Of Nuclear Medicine And Molecular Imaging 2022, 50: 921-928. PMID: 36282299, DOI: 10.1007/s00259-022-06002-5.Peer-Reviewed Original ResearchConceptsSelective internal radiation therapyTextbook outcomeInternal radiation therapyHepatocellular carcinomaRadiation therapyPatient-important outcomesLarge observational studiesNuclear medicine physiciansEntire intervention processRandomized trialsRoutine careResultsA totalObservational studyMultistep interventionMedicine physiciansInterventional radiologistsSenior authorClinical roundsCarcinomaTherapyInterventionOutcomesLocoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice?
Wang Y, Strazzabosco M, Madoff DC. Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice? Current Oncology Reports 2022, 24: 1741-1750. PMID: 36255606, PMCID: PMC10878124, DOI: 10.1007/s11912-022-01338-5.Peer-Reviewed Original ResearchConceptsLocoregional therapyIntrahepatic cholangiocarcinomaManagement of ICCFuture prospective randomized studiesComparable survival outcomesSafety of hepatectomyProspective Randomized StudyLocal tumor controlNon-surgical approachCurrent clinical practicePurpose of reviewUnresectable diseaseSurgical candidatesSystemic therapyVenous embolizationRandomized studyTransarterial embolizationDismal prognosisMultimodal treatmentSafety profileSurvival outcomesAblative therapyTumor controlPreoperative hypertrophyLiver lobeLong-Term Survival After Surgery Versus Ablation for Early Liver Cancer in a Large, Nationally Representative Cohort
Charalel RA, Mushlin AI, Li D, Mao J, Ibrahim S, Carlos R, Kwan SW, Fortune B, Talenfeld AD, Brown RS, Madoff DC, Johnson MS, Sedrakyan A. Long-Term Survival After Surgery Versus Ablation for Early Liver Cancer in a Large, Nationally Representative Cohort. Journal Of The American College Of Radiology 2022, 19: 1213-1223. PMID: 36208842, DOI: 10.1016/j.jacr.2022.07.010.Peer-Reviewed Original ResearchConceptsCancer-specific survivalSurgical resectionSmall hepatocellular carcinomaPrior treatment groupsHepatocellular carcinomaSurvival outcomesTreatment groupsSR groupPrior treatmentEnd Results Program-MedicarePropensity-matched hazard ratiosPropensity score-matched comparisonMedian study followNationally Representative CohortCancer-specific mortalityDisease-free survivalCox regression analysisKaplan-Meier curvesLog-rank testEarly liver cancerDifferential survival outcomesHealthcare Common Procedure Coding SystemCause mortalityCause survivalLiver transplantNight Watch: Positive Effect of a Night Float Call System on IR Resident Wellness
Chan SM, Laage Gaupp FM, Green CS, Malpani R, Madoff DC. Night Watch: Positive Effect of a Night Float Call System on IR Resident Wellness. Journal Of Vascular And Interventional Radiology 2022, 33: 1616-1618. PMID: 36049663, DOI: 10.1016/j.jvir.2022.08.025.Peer-Reviewed Original ResearchMachine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study.
Iseke S, Zeevi T, Kucukkaya AS, Raju R, Gross M, Haider SP, Petukhova-Greenstein A, Kuhn TN, Lin M, Nowak M, Cooper K, Thomas E, Weber MA, Madoff DC, Staib L, Batra R, Chapiro J. Machine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study. American Journal Of Roentgenology 2022, 220: 245-255. PMID: 35975886, PMCID: PMC10015590, DOI: 10.2214/ajr.22.28077.Peer-Reviewed Original ResearchConceptsEarly-stage hepatocellular carcinomaLiver transplantHepatocellular carcinomaImaging featuresPosttreatment recurrenceOrgan allocationMean AUCLiver transplant eligibilityPretreatment clinical characteristicsPretreatment MRI examinationsKaplan-Meier analysisKaplan-Meier curvesClinical characteristicsImaging surveillanceTherapy allocationTransplant eligibilityUnderwent treatmentClinical parametersRetrospective studyUnpredictable complicationMRI dataConcept studyPoor survivalClinical impactPretreatment MRIAn Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma
Madoff DC, Abi-Jaoudeh N, Braxton D, Goyal L, Jain D, Odisio BC, Salem R, Schattner M, Sheth R, Li D. An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma. The Oncologist 2022, 27: 884-891. PMID: 35925597, PMCID: PMC9526481, DOI: 10.1093/oncolo/oyac139.Peer-Reviewed Original ResearchConceptsIntrahepatic cholangiocarcinomaBiomarker testingMultidisciplinary teamImage-guided liver biopsyMetastatic intrahepatic cholangiocarcinomaEvidence-based guidelinesIntrahepatic biliary treeNext-generation sequencingActionable genetic alterationsTreatment landscapeLiver biopsyMedical oncologistsInterventional oncologistsPoor prognosisAggressive malignancyBiliary treeTissue acquisitionBiopsy methodImaging modalitiesDesmoplastic natureGenetic alterationsTissue collectionNeedle choicePrecision medicineCholangiocarcinomaDragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy
Korenblik R, Olij B, Aldrighetti LA, Hilal MA, Ahle M, Arslan B, van Baardewijk LJ, Baclija I, Bent C, Bertrand CL, Björnsson B, de Boer MT, de Boer SW, Bokkers RPH, Rinkes IHMB, Breitenstein S, Bruijnen RCG, Bruners P, Büchler MW, Camacho JC, Cappelli A, Carling U, Chan BKY, Chang DH, choi J, Font JC, Crawford M, Croagh D, Cugat E, Davis R, De Boo DW, De Cobelli F, De Wispelaere JF, van Delden OM, Delle M, Detry O, Díaz-Nieto R, Dili A, Erdmann JI, Fisher O, Fondevila C, Fretland Å, Borobia FG, Gelabert A, Gérard L, Giuliante F, Gobardhan PD, Gómez F, Grünberger T, Grünhagen DJ, Guitart J, Hagendoorn J, Heil J, Heise D, Herrero E, Hess GF, Hoffmann MH, Iezzi R, Imani F, Nguyen J, Jovine E, Kalff JC, Kazemier G, Kingham TP, Kleeff J, Kollmar O, Leclercq WKG, Ben SL, Lucidi V, MacDonald A, Madoff DC, Manekeller S, Martel G, Mehrabi A, Mehrzad H, Meijerink MR, Menon K, Metrakos P, Meyer C, Moelker A, Modi S, Montanari N, Navines J, Neumann UP, Peddu P, Primrose JN, Qu X, Raptis D, Ratti F, Ridouani F, Rogan C, Ronellenfitsch U, Ryan S, Sallemi C, Moragues JS, Sandström P, Sarriá L, Schnitzbauer A, Serenari M, Serrablo A, Smits MLJ, Sparrelid E, Spüntrup E, Stavrou GA, Sutcliffe RP, Tancredi I, Tasse JC, Udupa V, Valenti D, Fundora Y, Vogl TJ, Wang X, White SA, Wohlgemuth WA, Yu D, Zijlstra IAJ, Binkert CA, Bemelmans MHA, van der Leij C, Schadde E, van Dam RM. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy. CardioVascular And Interventional Radiology 2022, 45: 1391-1398. PMID: 35790566, PMCID: PMC9458562, DOI: 10.1007/s00270-022-03176-1.Peer-Reviewed Original ResearchConceptsFuture liver remnant hypertrophyHepatic vein embolizationMulticenter prospective single-arm trialResectable colorectal cancer liver metastasesColorectal cancer liver metastasesProspective single-arm trialFeasibility of resectionCancer liver metastasesDisease-free survivalSingle-arm trialSmall FLRPrimary endpointSecondary endpointsFLR hypertrophyLiver metastasesOverall survivalProspective trialVein embolizationLiver functionSafety profileArm trialLiver volumeWeek 1Week 3Study centersRandomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. CardioVascular And Interventional Radiology 2022, 45: 405-412. PMID: 35119481, PMCID: PMC8940827, DOI: 10.1007/s00270-021-03031-9.Peer-Reviewed Original ResearchConceptsBlinded independent central reviewIntermediate-stage hepatocellular carcinomaDisease control rateObjective response rateProgression-free survivalDuration of responseHepatocellular carcinomaCurative treatmentRECIST 1.1Primary endpointClinical benefitControl rateEastern Cooperative Oncology Group performance status 0Response rateChild-Pugh class ARandomized phase 3 studyDual primary endpointsOverall survival eventsPerformance status 0Previous systemic treatmentPD-1 inhibitorsPortal vein thrombosisPhase 3 studyResponse Evaluation CriteriaSolid Tumors 1.1Bronchial artery embolization for hemoptysis in a postpartum patient via cesarean section with COVID-19 while on extracorporeal membrane oxygenation
Lee M, Cornman-Homonoff J, Madoff DC. Bronchial artery embolization for hemoptysis in a postpartum patient via cesarean section with COVID-19 while on extracorporeal membrane oxygenation. Clinical Imaging 2022, 83: 123-130. PMID: 35033849, PMCID: PMC8743280, DOI: 10.1016/j.clinimag.2021.12.017.Peer-Reviewed Case Reports and Technical NotesKidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 71-90. PMID: 34991070, PMCID: PMC10191161, DOI: 10.6004/jnccn.2022.0001.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaStage IV renal cell carcinomaNCCN guidelinesKidney cancerTreatment selectionNCCN Clinical Practice GuidelinesAdvanced renal cell carcinomaSystemic therapy recommendationsFirst-line treatmentPre-existing comorbiditiesClinical practice guidelinesKidney cancer therapyRecommended regimensSystemic therapyRisk stratificationTumor histologyCell carcinomaTreatment recommendationsTherapy recommendationsRisk groupsPractice guidelinesCancer fociTherapy selectionCancer panelPatients
2021
Quantitative Automated Segmentation of Lipiodol Deposits on Cone-Beam CT Imaging Acquired during Transarterial Chemoembolization for Liver Tumors: A Deep Learning Approach
Malpani R, Petty CW, Yang J, Bhatt N, Zeevi T, Chockalingam V, Raju R, Petukhova-Greenstein A, Santana JG, Schlachter TR, Madoff DC, Chapiro J, Duncan J, Lin M. Quantitative Automated Segmentation of Lipiodol Deposits on Cone-Beam CT Imaging Acquired during Transarterial Chemoembolization for Liver Tumors: A Deep Learning Approach. Journal Of Vascular And Interventional Radiology 2021, 33: 324-332.e2. PMID: 34923098, PMCID: PMC8972393, DOI: 10.1016/j.jvir.2021.12.017.Peer-Reviewed Original ResearchBalloon-assisted radioembolization via the proper hepatic artery to treat a left liver hepatocellular carcinoma and portal vein tumor thrombus with an inaccessible left hepatic artery: A case report
Mabey JG, Cornman-Homonoff J, Madoff DC. Balloon-assisted radioembolization via the proper hepatic artery to treat a left liver hepatocellular carcinoma and portal vein tumor thrombus with an inaccessible left hepatic artery: A case report. Clinical Imaging 2021, 82: 244-250. PMID: 34920388, DOI: 10.1016/j.clinimag.2021.11.026.Peer-Reviewed Case Reports and Technical NotesConceptsPortal vein tumor thrombusLeft hepatic arteryProper hepatic arteryHepatic arteryVein tumor thrombusHepatocellular carcinomaTransarterial radioembolizationTumor thrombusUse of TAREYttrium-90 transarterial radioembolizationTumor-feeding vesselsLiver hepatocellular carcinomaBalloon occlusionCase reportBalloon microcatheterVessel angulationEffective treatmentLiver parenchymaArteryTumor vesselsY microspheresRadiotracer activityRadioembolizationCarcinomaThrombusSystematic Reviews and Meta-Analyses of Portal Vein Embolization, Associated Liver Partition and Portal Vein Ligation, and Radiation Lobectomy Outcomes in Hepatocellular Carcinoma Patients
Charalel RA, Sung J, Askin G, Jo J, Mitry M, Chung C, Tmanova L, Madoff DC. Systematic Reviews and Meta-Analyses of Portal Vein Embolization, Associated Liver Partition and Portal Vein Ligation, and Radiation Lobectomy Outcomes in Hepatocellular Carcinoma Patients. Current Oncology Reports 2021, 23: 135. PMID: 34716800, DOI: 10.1007/s11912-021-01075-1.Peer-Reviewed Original ResearchConceptsPortal vein embolizationAssociated liver partitionPortal vein ligationHepatocellular carcinoma patientsSystematic reviewVein embolizationCarcinoma patientsMajor complicationsPooled proportionVein ligationLiver partitionLow major complication rateMajor complication ratePurpose of ReviewToRandom-effects modelWeb of ScienceEffective hypertrophyFLR hypertrophyComplication rateOvid EmbaseCochrane LibraryHCC patientsLiver hypertrophyOvid MEDLINEInclusion criteriaConventional Hepatic Volumetry May Lead to Inaccurate Segmental Yttrium-90 Radiation Dosimetry
Stein SI, Soliman MM, Sparapani J, Doustaly R, Cobb BW, Malhotra A, Charalel R, May BJ, Lee KS, Madoff DC, Talenfeld AD. Conventional Hepatic Volumetry May Lead to Inaccurate Segmental Yttrium-90 Radiation Dosimetry. CardioVascular And Interventional Radiology 2021, 44: 1973-1985. PMID: 34414494, DOI: 10.1007/s00270-021-02898-y.Peer-Reviewed Original ResearchConceptsMedical Internal Radiation DosimetryCone-beam CTCT/MRI scansSegmental volumesVariant arterial anatomyCT/MRIWilcoxon signed-rank testY90 radioembolizationZone volumeArterial anatomyVenous anatomyTumor locationSigned-rank testInternal radiation dosimetryHepatic volumetryMRI scansLobar volumesVolumetric differencesCouinaudDose targetsPersonalized dosimetryBeam CTAngiogramsDosesVolumetryCommentary on: "Rebleeding and Mortality Risk Are Increased by ACLF but Reduced by Pre-emptive TIPS".
Cornman-Homonoff J, Madoff D. Commentary on: "Rebleeding and Mortality Risk Are Increased by ACLF but Reduced by Pre-emptive TIPS". American Journal Of Roentgenology 2021, 216: 878. PMID: 33025807, DOI: 10.2214/ajr.20.24811.Commentaries, Editorials and LettersThermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient groupManagement of Refractory Ascites Due to Portal Hypertension: Current Status.
Madoff DC, Cornman-Homonoff J, Fortune BE, Gaba RC, Lipnik AJ, Yarmohammadi H, Ray CE. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021, 298: 493-504. PMID: 33497318, DOI: 10.1148/radiol.2021201960.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRefractory ascitesPortal hypertensionTransjugular intrahepatic portosystemic shuntLarge-volume paracentesesCirrhotic portal hypertensionAvailable therapeutic optionsIntrahepatic portosystemic shuntStepwise management approachMost patientsMedical managementPoor prognosisPortosystemic shuntTherapeutic optionsTreatment optionsMultiple therapiesPatient outcomesAppropriate treatmentClinical experienceDrainage deviceSpecific patientAscitesHypertensionPatientsParacentesesPrognosisInternational recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres
Levillain H, Bagni O, Deroose CM, Dieudonné A, Gnesin S, Grosser OS, Kappadath SC, Kennedy A, Kokabi N, Liu DM, Madoff DC, Mahvash A, Martinez de la Cuesta A, Ng DCE, Paprottka PM, Pettinato C, Rodríguez-Fraile M, Salem R, Sangro B, Strigari L, Sze DY, de Wit van der veen BJ, Flamen P. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. European Journal Of Nuclear Medicine And Molecular Imaging 2021, 48: 1570-1584. PMID: 33433699, PMCID: PMC8113219, DOI: 10.1007/s00259-020-05163-5.Peer-Reviewed Original ResearchConceptsSelective internal radiation therapyInternal radiation therapyActivity prescriptionRadiation therapyLiver metastatic colorectal cancerYttrium-90 resin microspheresResin microspheresMetastatic liver diseaseMetastatic colorectal cancerMultidisciplinary expert panelNon-tumoural liverSPECT/CTLiver diseaseColorectal cancerTreatment strategiesHepatocellular carcinomaSteering CommitteePost-treatment dosimetryYttrium-90Multidisciplinary teamTherapeutic intentMicrosphere activityWhole liverLiterature searchLevel of agreement